Search company, investor...
Search
Galena Biopharma company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

galenabiopharma.com

Stage

Acq - P2P | Acquired

About Galena Biopharma

Galena Biopharma (Nasdaq: GALE) is a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care.

Galena Biopharma Headquarters Location

2000 Crow Canyon Place Suite 380

San Ramon, California, 94583,

United States

855-855-4253

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Galena Biopharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Galena Biopharma is included in 1 Expert Collection, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Galena Biopharma Patents

Galena Biopharma has filed 2 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immunology
  • Monoclonal antibodies
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/16/2018

5/24/2022

Clusters of differentiation, Transcription factors, Monoclonal antibodies, Oncology, Immunology

Grant

Application Date

1/16/2018

Grant Date

5/24/2022

Title

Related Topics

Clusters of differentiation, Transcription factors, Monoclonal antibodies, Oncology, Immunology

Status

Grant

Latest Galena Biopharma News

SELLAS Life Sciences Announces Final Court Approval of Settlement of Securities Litigation

Feb 28, 2022

New York, New York, UNITED STATES NEW YORK, Feb. 28, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc.  (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that on February 24, 2022 the United States District Court for the District of New Jersey issued final approval of the settlement of the claims relating to the Company’s predecessor, Galena Biopharma, Inc., in the litigation captioned In re Galena BioPharma, Inc. Securities Litigation. The settlement provides for the payment of $1,600,000 to a settlement fund which is to be distributed to members of the plaintiff class after accounting for fees and expenses, which amount is fully covered by insurance. “The final court approval for the settlement of the securities litigation marks the end of all legacy litigation related to Galena, our predecessor,” said Angelos M. Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS. “I am pleased that our legal team was able to strike such a modest settlement payment, fully covered by insurance, as SELLAS continues to be focused on continuing our diligent work to develop innovative novel cancer immunotherapies to provide much needed, more tolerable, therapeutic treatment options for patients – that is our mission.” About SELLAS Life Sciences Group, Inc. SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential both as a monotherapy and in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS’ second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer patients, following the standard of care. For more information on SELLAS, please visit www.sellaslifesciences.com . Investor Contacts

  • Where is Galena Biopharma's headquarters?

    Galena Biopharma's headquarters is located at 2000 Crow Canyon Place, San Ramon.

  • What is Galena Biopharma's latest funding round?

    Galena Biopharma's latest funding round is Acq - P2P.

  • Who are the investors of Galena Biopharma?

    Investors of Galena Biopharma include Sellas and RXi Pharmaceuticals.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.